Reference | N.pts | Type of cancer | Primary/recurrent | EBRT N. pts Dose (Gy) | IORT dose (Gy) | Technique | Median follow-up months(range) | Local Control | Overall Survival | Toxicity |
---|---|---|---|---|---|---|---|---|---|---|
Sole [7] | 61 | Uterus 18 Cervix 32 Other 11 | Pelvic recurrent 35 (57%) Paraortic recurrent 26 (43%) | Mean 31 Gy (29–45) | R0: 10–12.5 Gy R1: 15 Gy | IOERT | 42 (2–169) | 5-years 65% | 5-years 42% | RTOG acute ≥ G3: 23 RTOG late ≥ G3: GI 8 GU 3 Neuropathy 1 |
Foley [8] | 32 | Cervix 21 Uterus 6 Other 5 | Pelvic recurrent 26 (81%) Primary 6 (19%) | NA | Mean 13.5 Gy (10–22.5) | IOERT | Median 26 (3–196) | 5-years R1 73% 5 years R2 71% | 5-years 70% R1 77% R2 55% | ≥G3 47% 5 IORT-related GU 2 Bone 1 Lymphedema 2 |
Backes [9] | 32 21 IORT | Cervix 21 Other 11 | Recurrent 32 (100%) | 6 pts, mean 26 Gy (10–40) | Median 17.5 Gy (10–20 Gy) | IOERT HDR IORT | NA | Median PE + IORT 10 months LEER + IORT 9 months PE 33 months | Median PE + IORT 10 months LEER + IORT 17 months PE 41 months | NA |
Barney [10] | 86 | Cervix | Pelvic recurrent 73 (85%) Primary 13 (15%) | 61 pts (71%) No prior RT: median 45 Gy Prior RT: median 39.6 Gy | median 15 Gy (6–25 Gy) | IOERT | 32 (1–306) | 3-years 62%: 70% primary 61% recurrent | 3-years 25% | ≥G3 GI 4 GU 1 Neuropathy 1 Other 4 |
Calvo [11] | 35 | Uterus 7 Cervix 20 Other 8 | Pelvic recurrent 35 (100%) | 16 pts: 45 Gy no previous RT 30.6 Gy previous RT | R0: 10–12.5 Gy R1: 15 Gy | IOERT | 46 (3–169) | 5-years 58% | 5-years 42% | acute ≥3: 14 late ≥3: GI 5 GU 2 Neuropathy 1 |
Giorda [12] | 35 | Cervix | Primary 35 (100%) | neoadj 50.4 Gy | Mean 11 Gy (10–15) | IOERT | NA | 2-years 89% | 5-years 49% | Peri/post-surgery GU 10 |
Tran [13] | 36 | Cervix 17 Uterus 11 Other 8 | Recurrent 32 (88%) | 18 pts (50%) mean 44 Gy | Median 11.5 Gy (6–17.5) | Orthovoltage-IORT | Mean 50 (2–198) | 5-years 44% Cervix 45% Uterus 58% | 5-years 42% | ≥G3 10 pts 28% |
Dowdy [14] | 25 | Uterus | Recurrent 25 (100%) | 21 pts 45 Gy | Median 15 Gy (10–25 Gy) | IOERT | Median 34 | 84% | 5-years: 71% R0 47% R1 0% R2 | Neuropathy 8 GU 5 Fistulas 5 Bone fractures 2 |
Awtrey [15] | 27 | Uterus | Pelvic Recurrent 27 (100%) | 12 pts | NA | IOERT 9 pts | Median 24 (5–84) | NA | 2-years 78% | NA |
Martinez-Monge [16] | 67 | Cervix | Pelvic Recurrent 36 (54%) Primary 31 (46%) | 36 pts : 45 Gy | Primary: 12 Gy median (10–25) Recurrent: 15 Gy (10–20) | IOERT | Primary: 58 (8–144) Recurrent 19 (1–138) | 10-year 69%: 93% primary 47% recurrent | 10-year 35%; 58% primary 14% recurrent | 15% IORT related |
Gemignani [17] | 17 | Cervix 9 Uterus 7 Other 1 | Recurrent 17 (100%) | 2 pts dose NA | Mean 14Gy (12-15Gy) | HDR-IORT | 20 (3–65) | 67 | 54 | NA |
DelCarmen [18] | 15 | Cervix 5 Uterus 3 Other 7 | Pelvic Recurrent 14 (93%) Primary 1 (7%) | - | 10-22.5 Gy | IOERT | (3–36) | 54% | 74% | Neuropathy 4 GU 3 Lymphedema 2 |
Garton [19] | 39 | Cervix 22 Uterus 10 Other 7 | Pelvic Recurrent 36 (92%) Primary 3 (8%) | 28 pts Median 45 Gy (1–67) | Median 17.3 Gy (10–25 Gy) | IOERT | Median 25 (6–125) | 5-years 67% | 5-years 32% | ≥G3 14 (36%) IORT related 6 |
Mahè [20] | 70 | Cervix | Pelvic Recurrent 70 (100%) | 30 pts (20–45) | R0 mean 18 (10–25) R1-biopsy mean 19 (10–30) | IOERT | Mean 15 (2–69) | 21% R0 27% R1-2 11% | 3-years 8% | 10-IORT related GI 1 GU 4 Neuropathy 5 |
Stelzer [21] | 22 | Cervix | Pelvic Recurrent 22 (100%) | 6 pts: 26–50 Gy 7 pts: 45–62.4 Gy | 22 Gy median (14–27.8 Gy) | IOERT | Minimum 15 months | 5-years 48% | 5-years 43% | Neuropathy 7 |